MRNA · Moderna Inc
Price
Snapshot
50 fields · last close| Market Cap | $94.42B |
| P/E | — |
| Float | 367.8M |
| Beta | 1.18 |
| Volatility | 29.4% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 18.4 |
| Price | 215.18 |
| Change | −1.30% |
| Prev Close | 218.01 |
| Open | 225.48 |
| Day Low | 217.02 |
| Day High | 242.29 |
| Avg Vol | 19 |
| Avg $ Vol | $4.44B |
| 52W High | 236.50 |
| 52W Low | 22.28 |
| 52W Pos | 90.0% |
| From High | −9.01% |
| From Low | +865.80% |
| Max DD 1Y | −34.16% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +8.69% |
| SMA 50 | +41.89% |
| SMA 200 | +181.43% |
| RSI (14) | 71.7 |
| Vol 30D | 78.5% |
| Vol 90D | 193.3% |
| 1Y Range | 22–236 |
| Daily bars | 535 |
| Perf Week | +20.05% |
| Perf Month | +62.41% |
| Perf Quarter | +282.56% |
| Perf Half Y | +332.52% |
| Perf Year | +800.95% |
| Perf YTD | +597.28% |
| Prev Day | −1.30% |
| Clavix | F |
| Debt / Eq | 0.07 |
| Curr Ratio | 3.29 |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | −39.9% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 35 / 35 |
What MRNA does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Clavix risk grade
regraded every trading dayMRNA grades F, 18.4 of 100. Steadiest on News Sentiment (47), most exposed on Price Stability (6, weak). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 35 of 35 in Biotechnology by Clavix score.
How rough the ride is
| MRNA | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.18 | 0.50 |
| Volatilityannualized | 29.4% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −34.2% | — |
| Typical daily movemedian absolute daily change | 2.61% | — |
| Days beyond ±3%of the last 252 sessions | 115 (46%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MRNA | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.18 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MRNA | |
|---|---|
| 1 week | +20.1% |
| 1 month | +62.4% |
| Year to date | +597.3% |
| 1 year | +801.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MRNA | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 11 Sep |
| Average score0 most bearish, 100 most bullish | 64 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 4 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| MRNA | |
|---|---|
| Revenue growthyear over year | −39.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openModerna shares rose more than 14% on Friday after The New York Times reported that the National Institutes of Health plans to launch a major campaign in December to fast-track cancer treatment research, modeled on the rapid Covid-19 vaccine development effort. The article suggests Moderna could play a significant role given its biotech expertise, though no specific company involvement was confirmed.
Moderna's stock rose after the company reported promising results for its experimental cancer therapy in a clinical trial, and as the National Institutes of Health (NIH) is reportedly planning to launch a broader cancer vaccine development program.
Moderna shares hit a new 52-week high on Friday. Three things drove the move: Moderna rejoined the Nasdaq-100 index, the New York Times reported a planned cancer-vaccine effort backed by the National Institutes of Health (NIH), and an analyst raised their price target for the stock.
Moderna's shares are up over 560% this year, far ahead of the S&P 500's roughly 14% gain, driven by clinical and regulatory progress including FDA approval of its influenza vaccine mFLUSIVA for adults 50 and older. Wall Street analysts cited by Yahoo!
Moderna stock rose 9% on Friday after a New York Times report detailed a planned national effort to speed up cancer vaccine development, with investors viewing the mRNA biotech as a key beneficiary.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | B+ | $81.99B | 19.00 | 0.13 | Compare |
| VRTX | Vertex Pharmaceuticals Inc | B+ | $128.9B | 29.32 | 0.28 | Compare |
| NTRA | Natera Inc | B- | $58.35B | — | 1.54 | Compare |
| GILD | Gilead Sciences, Inc | A- | $195.1B | 23.21 | 0.40 | Compare |
| RVMD | Revolution Medicines Inc | B- | $40.57B | — | 1.43 | Compare |
| AMGN | Amgen Inc | A- | $234.7B | 26.35 | 0.44 | Compare |
| BIIB | Biogen Inc | B+ | $34.77B | 42.27 | 0.10 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $31.32B | 37.17 | 0.37 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.